Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents-Reference-Cited by-同舟云学术

Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents

Published:2014-02 Issue:1 Volume:40 Page:170-177
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Bahl Amit,Masson Susan,Birtle Alison,Chowdhury Simon,de Bono Johann

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference37 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. 2010; Available from: [Accessed March 2013].

2. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Prostate Cancer (Version 3.2012). 2012; Available from: [Accessed March 2013].

3. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Horwich;Ann Oncol,2010

4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on Prostate Cancer. 2012; Available from: [Accessed March 2].

5. Omlin A, Pezaro C, Mukherji D, et al. Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. Eur Urol 64, 2013, 300–306.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, development, and in-vitro/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy;European Journal of Pharmaceutics and Biopharmaceutics;2023-08

2. Sympathetic β2-adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer;Biochemical and Biophysical Research Communications;2023-05

3. Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7;Cell Death Discovery;2022-05-03

4. Silencing of circDPP4 suppresses cell progression of human prostate cancer and enhances docetaxel cytotoxicity through regulating the miR‐564/ZIC2 axis;The Journal of Gene Medicine;2022-01-23

5. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells;Journal of Biological Chemistry;2019-05